- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment closed: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Oct 10, 2024
P2, N=30, Active, not recruiting,
Initiation date: Oct 2024 --> Feb 2025 Recruiting --> Active, not recruiting
- |||||||||| Trial initiation date, Trial primary completion date: Human Models of Selective Insulin Resistance: Pancreatic Clamp (clinicaltrials.gov) - Sep 20, 2024
P1, N=36, Not yet recruiting,
Recruiting --> Suspended Initiation date: Sep 2024 --> Dec 2024 | Trial primary completion date: Aug 2026 --> Dec 2026
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Aug 7, 2024
P2, N=30, Recruiting,
Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- |||||||||| Preclinical, Journal: Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding. (Pubmed Central) - Jul 31, 2024
Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions.
- |||||||||| dexamethasone / Generic mfg.
Enrollment change, Trial withdrawal: Dexamethasone/Pancreatic Clamp P&F (clinicaltrials.gov) - Jul 9, 2024
P1, N=0, Withdrawn,
An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions. N=16 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Preclinical, Journal: In Vitro Investigation of Insulin Dynamics During 4 Hours of Simulated Cardiopulmonary Bypass. (Pubmed Central) - Jun 11, 2024
The decrease was more pronounced in the cECC, which also exhibited a greater degree of hemolysis. Our results suggest that insulin degradation by hemolysis products may be a stronger contributor to insulin loss than adhesion of insulin molecules to circuit surfaces.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Journal: Pigs are highly susceptible to but do not transmit mink-derived highly pathogenic avian influenza virus H5N1 clade 2.3.4.4b. (Pubmed Central) - May 26, 2024
ABSTRACTRapid evolution of highly pathogenic avian influenza viruses (HPAIVs) is driven by antigenic drift but also by reassortment, which might result in robust replication in and transmission to mammals...Notably, critical mammalian-like mutations such as PB2-E627K and HA-Q222L emerged at low frequencies in principal-infected pigs. It is concluded that pigs are highly susceptible to infection with the mink-derived clade 2.3.4.4b H5N1 HPAIV and provide a favorable environment for HPAIV to acquire mammalian-like adaptations.
- |||||||||| dexamethasone / Generic mfg.
Trial initiation date: Dexamethasone/Pancreatic Clamp P&F (clinicaltrials.gov) - Apr 18, 2024
P1, N=16, Not yet recruiting,
It is concluded that pigs are highly susceptible to infection with the mink-derived clade 2.3.4.4b H5N1 HPAIV and provide a favorable environment for HPAIV to acquire mammalian-like adaptations. Initiation date: Dec 2023 --> Jul 2024
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial primary completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Apr 4, 2024
P2, N=30, Recruiting,
Initiation date: Dec 2023 --> Jul 2024 Trial primary completion date: Mar 2024 --> Jun 2024
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: COMMETS- Combination MCI Metabolic Syndrome (clinicaltrials.gov) - Mar 22, 2024
P2, N=80, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial initiation date, Trial primary completion date: ITA: Intranasal Insulin for Treatment of Alcohol Use Disorder (clinicaltrials.gov) - Jan 11, 2024
P1/2, N=40, Not yet recruiting,
Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> May 2024 Trial completion date: Sep 2024 --> Jan 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2024 --> Jan 2025
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Dec 6, 2023
P2, N=30, Recruiting,
Trial completion date: Sep 2024 --> Jan 2025 | Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Sep 2024 --> Jan 2025 Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Oct 2023 --> Mar 2024
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Sep 6, 2023
P2/3, N=30, Not yet recruiting,
Active, not recruiting --> Completed Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
PK/PD data, Journal: Pharmacokinetics, pharmacodynamics, and safety of prandial oral insulin (N11005) in healthy subjects. (Pubmed Central) - Aug 15, 2023
P1
To verify whether the oral insulin N11005 is administered as a prandial insulin by assessing the pharmacokinetics (PK), pharmacodynamics (PD), and safety profiles of N11005 with a short-acting biosynthetic human insulin (Novolin R) as reference...The PD profiles of the single-dose N11005 in the human body are similar to those of prandial insulins, with an excellent safety profile. Clinicaltrials.gov, identifier NCT04975022.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial completion date, Trial primary completion date: INI-PD: Intranasal Insulin in Parkinson's Disease (clinicaltrials.gov) - Jul 12, 2023
P2, N=30, Recruiting,
Clinicaltrials.gov, identifier NCT04975022. Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment change, Trial termination: Intranasal Insulin in Frontotemporal Dementia (FTD) (clinicaltrials.gov) - Jul 6, 2023
P2, N=3, Terminated,
Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Oct 2023 N=12 --> 3 | Suspended --> Terminated; COVID - unable to restart after restrictions were lifted
- |||||||||| Betadine (povidone iodine) / Egis, Novolin R (recombinant human insulin) / Novo Nordisk
Topical insulin in the treatment of non-healing erosions and ulcers of pemphigus vulgaris () - Jul 3, 2023 - Abstract #WCD2023WCD_5099;
He was receiving systemic steroid, antibiotics and other supportive measures with daily wound care with paraffin-embedded sterile gauze sheets, still the ulcers did not heal.The ulcers and erosions were cleaned with normal saline and betadine. 0.5-1ml insulin (Human actrapid insulin 40IU/ml
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Jun 15, 2023
P2/3, N=30, Not yet recruiting,
On right side of the face, 1-2ml TI (Human actrapid insulin 40IU/ml Trial primary completion date: Sep 2023 --> Dec 2023
- |||||||||| Insulatard (isophane insulin) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Novolin R (recombinant human insulin) / Novo Nordisk
Journal: ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS CHILDREN WITH DIABETES MELLIUS TYPE 1 USING DIFFERENT TYPES OF INSULIN PREPARATIONS. (Pubmed Central) - May 15, 2023
Group 1 included 20 children who used Insulin human (Insulatard), group 2 included 15 children using insulin Glargine, and group 3 included 14 children using insulin Detemir...Those using Insulin human (Insulatard) used Human insulin (rDNA, Actrapid) in addition...However, no such relationship between Glargine, body mass and height was recorded. It was a negative correlation between its dose Glargine with glycohemoglobin and also between glucose and cholesterol using Glargine.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Diabetic Ketoacidosis Management with Sliding Scale in a Pregnant Woman (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1043;
She was previously known as diabetic using Metformin and she abandoned that medication 2years ago...Her capillary blood glucose was24.7 mmol/L (446 mg/dl) with positive urine ketones of 16 mmol/L and urine glucose of 110 mmol/L.At the same time, while the SSM with insulin bolus was started with 10 units of Actrapid 100 i.u (fastacting human insulin) subcutaneously injected in abdominal wall and following the table 1 every 2hours for specific dose up to the steady state of glycaemia, deep blood and imaging tests wereperformed such as maternal potassium level in other to optimize treatment...Obstetric ultrasound has been performed and any fetal malformation has notbeen seen and determined 22 weeks of gestation. This case shows the prompt andaccurate diagnosis of DKA in pregnancy and the benefit of the SSM leading to both optimal maternaland fetal outcomes.Keywords: DKA: Diabetic Ketoacidosis, SSM: Sliding Scale Management
- |||||||||| GlucaGen (recombinant glucagon) / Novo Nordisk, Novolin R (recombinant human insulin) / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: HypoADAPT: Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes (clinicaltrials.gov) - Feb 23, 2023
P=N/A, N=60, Active, not recruiting,
Trial primary completion date: Dec 2022 --> Aug 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Jan 31, 2023
P2/3, N=30, Not yet recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial primary completion date: Mar 2023 --> Sep 2023
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Journal: Beneficial effects of Plasma Rich in Growth Factors (PRGF) versus autologous serum and topical insulin in ocular surface cells. (Pubmed Central) - Jan 26, 2023
Insulin (Actrapid ®) was diluted at 1 and 0.2 IU/mL...Furthermore, PRGF significantly reduced the number of myodifferentiated cells compared to AS and insulin at both concentrations analyzed. The results obtained in the present study show that PRGF increases the biological activity of the ocular surface cells and reduces the expression of fibrosis marker compared to insulin or AS.Translational Relevance: The present study suggests that plasma rich in growth factors eye drops are a more effective therapy than insulin and autologous serum eye drops for the treatment of ocular surface diseases.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Trial primary completion date: Intranasal Insulin in Frontotemporal Dementia (FTD) (clinicaltrials.gov) - Jan 17, 2023
P2, N=12, Suspended,
The results obtained in the present study show that PRGF increases the biological activity of the ocular surface cells and reduces the expression of fibrosis marker compared to insulin or AS.Translational Relevance: The present study suggests that plasma rich in growth factors eye drops are a more effective therapy than insulin and autologous serum eye drops for the treatment of ocular surface diseases. Trial primary completion date: Dec 2022 --> Apr 2023
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
Journal: Stability of insulin eye drops in the treatment of refractory corneal ulcers. (Pubmed Central) - Dec 16, 2022
25 IU/mL insulin eye drops made with normal saline remain stable for 120 days whether they are stored at room temperature, in a refrigerator or in a freezer, provided that they are protected from light. When made with a balanced salt solution, they remain stable for 120 days at room temperature and in a freezer, their shelf life being reduced to 90 days in the case of storage in a refrigerator.
- |||||||||| 100 years with insulin. Implementation of analogs and technology in our environment (Rome, Italy) - Nov 13, 2022 - Abstract #ESPE2022ESPE_812;
Of the 6 pumps, they use lispro (4/6), aspartic (1/6) and another glulisine (1/6) Of the MDIs, as slow analogs NPH 0/65, detemir 12/65 (85% are <6 years), U100 10/65, U300 35/65 liraglutide 8/65...Of the MDIs, such as fast analogues è Actrapid 0/65, lispro 30/65 (1 U200 off labell per dose), aspartic 10/65, ultrafast (15/65) and glulisine 10/65 The indication has been for age, comfort, dose / need for stockings and a pen for this purpose and switch due to poor adjustment of the previous analog...There was no impediment by medical inspection in any prescription except in 1 case (belonging to another health area) with BAQSIMI Previous severe hypoglycemia with previous loss of consciousness in <5% of cases (0.03 patient / year cases)... We assume that this study may have some shortcomings due to the size of the sample, but our study demonstrates the implementation of the most modern analogs in the office, of measurement technology, but the need to advance in the use of insulin pumps.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk
A case of de novo ABCC8 gene mutation resulting in Transient Neonatal Diabetes (Rome, Italy) - Nov 13, 2022 - Abstract #ESPE2022ESPE_704;
Treatment with Actrapid 0.025 IU/Kg/hour was started...Glibenclamide was due to be started at 0.05 mg/Kg/day in two divided doses, however, infant's blood glucose levels stabilised at 4-7 mmol/l, decision was made to hold off sulfonylurea treatment...Despite remission, close glucose monitoring and education of caregivers about diabetes is essential. Long term monitoring is planned (to puberty) with a focus on possible diabetes relapse.
- |||||||||| Novolin R (recombinant human insulin) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date: LEV PS: Dose Response Study of Transdermal Human Insulin in Patients (clinicaltrials.gov) - Oct 13, 2022
P2/3, N=30, Not yet recruiting,
Long term monitoring is planned (to puberty) with a focus on possible diabetes relapse. Trial completion date: Dec 2022 --> Dec 2023 | Initiation date: Oct 2022 --> Jan 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
|
